Speakers
Isaac Garcia-Murillas
Michael Hubank
Masood Moghul
Science & Education
Room: Carlton Room
An exciting session looking at recent innovations in the field of cancer, covering advances in myeloma, the ManVan project, a genomics hub cancer perspective and ctDNA.
Isaac Garcia-Murillas 10:00 – 10:30 Clinical utility of circulating tumor DNA in early stage breast cancer
Michael Hubank 10:30 – 11:00
Masood Moghul 11:00 – 11:30 The Man Van Project
Kevin Boyd 11:30 – 12:00 Myeloma: Intersection with Biochemistry and Current Treatment Innovations
Dr Isaac Garcia-Murillas is a Staff Scientist at the Breast Cancer Now Research Centre at The Institute of Cancer Research in London where he leads and develops the use of Next Generation Sequencing (NGS) and digital PCR (dPCR) technologies to study circulating tumour DNA (ctDNA) from liquid biopsies. His research interests converge in the clinical utility of ctDNA as a potential biomarker to detect Minimal Residual Disease, monitor response to treatment, stratify patients to targeted therapies and identify the emergence of drug resistance.
Clinical Research Fellow – Urology (Man Van Project)
I am a final year urology trainee currently pursuing an MD(Res) under the joint supervision of Professor Nick James, Mr Declan Cahill and Professor Ros Eeles. I am working on the Man Van Project which is designed to increase patient access and support to cancer investigation pathways by offering targeted community testing for urological cancers and other health conditions.
Dr Kevin Boyd is a Consultant Haematologist at The Royal Marsden NHS Foundation Trust and Honorary Senior Clinical Lecturer at the Institute of Cancer Research, London. He has worked as a doctor in the NHS for almost 25 years, including the last 10 years as a Consultant Haematologist. On the clinical side he is clinical service lead for myeloma at the Royal Marsden Hospital where he carries out several specialist myeloma clinics per week. He is also involved in the regional Haematology Diagnostics Service at the Royal Marsden, which is a regional hub for flow cytometry, histology, cytogenetic and molecular diagnostics for Haematological malignancy.
He has a research interest in myeloma imaging, myeloma genetics and risk stratification, and clinical trials of novel therapies. In his work towards a PhD he designed a genetic risk stratification model that remains in widespread use today. He is currently a member of the myeloma NCRI studies subgroup and is on the trial management group of several national trials including MUK7, MUK12 and Myeloma XII as well as chairing the Trial Steering Committee of the Myeloma XI trial. He is local Principal Investigator for multiple clinical trials and is UK Chief Investigator of the DREAMM-7 study. He is Secretary of the UK Myeloma Forum Guidelines Committee and Chair of the London Clinical Guidelines Group. He is also a clinical advisor to Blood Cancer UK.